

The invention relates to the use of pharmaceutical compounds having NMDA antagonist activity for treating certain conditions in the gastrointestinal tract, such as functional gastrointestinal disorders, and in particular irritable bowel syndrome (IBS). The invention also relates to pharmaceutical compositions to be used in the treatment of IBS and product comprising such compounds and a pharmaceutical acceptable carrier.